Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 3, 1997, Pages 186-192

  Ma, Jianguo ^a   Maliepaard, Marc ^a,b   Kolker, Herman J ^a   Verweij, Jaap ^a   Schellens, Jan H M ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cellular uptake; Cisplatin; Energy depletion; Ovarian cancer; Resistance

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; CORRELATION FUNCTION; DRUG UPTAKE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031880819     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050727     Document Type: Article

References (33)

1. Ali-Osman F, Berg MS, Rajagopal S, Spence A, Livingston RB (1993) Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res 53: 5663
2. Andrews PA, Albright KD (1992) Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res 52: 1895
3. Andrews PA, Murphy MP, Howell SB (1987) Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 19: 149
4. Andrews PA, Velury S, Mann SC, Howell SB (1988) cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48: 68
5. +-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res 51: 3677
6. Benard J, Silva JD, De Blois MC, Boyer P, Chiric E, Riou G (1985) Characterization of a human ovarian adenocarcinoma line, IGROV-1, in tissue culture and in nude mice. Cancer Res 45: 4970
7. Fichtinger-Schepman AMJ, Velde-Visser SD vander, Dijk-Knijnenburg HCM van, Oosterom AT van, Baan RA, Berends F (1990) Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 50: 7887
8. Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171
9. Hospers GAP, Mulder NH, Jong B de, Ley L de, Uges RA, Fichtinger-Schepman AMJ, Scheper RJ, Vries EGE de (1988) Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res 48: 6803
10. Ishikawa T, Wright CD, Ishizuka H (1994) GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem 269: 29085
11. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, Kuo MT (1996) Coordinated induction of MRP GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271: 14981
12. Jong S de, Zijlstra JG, Timmer-Bosscha H, Mulder NH, Vries EGE de (1998) Determination of DNA cross-links in tumour cells with the ethidium bromide fluorescence assay. Int J Cancer 37: 557
13. Kawai K, Kamatani N, Kuroshima S, Noberi T, Nishiok K, Kamiya H, Sakurai M, Mikanagi K (1987) Cross-resistance to ouabain in a murine leukemia cell variant selected for cis-diamminedichloroplatinum(II) resistance. Cancer Lett 35: 147
14. Kawai K, Kamatani N, Georges E, Ling V (1990) Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J Biol Chem 265: 13137
15. Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188
16. Kuppen PJK, Schuitemaker H, Veer LJ van't, Bruijn EA de, Oosterom AT van, Schier PI (1988) cis-Diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumour cell lines. Cancer Res 48: 3355
17. Loehrer PJ, Einhorn LH (1984) Diagnosis and treatment: drug five years later. Cisplatin. Ann Intern Med 100: 704
18. Loh SY, Kelland LR, Abel G, Harrap KR (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum(II) and (IV) ammine amine complexes. Br J Cancer 66: 1109
19. Lowry OH, Rosebrough MT, Farr AL, Randall RJ (1951) Protein measurements with the Folin phenol reagent. J Biol Chem 193: 265
20. Ma J, Verweij J, Kolker HJ, Ingen HE van, Stoter G, Schellens JHM (1994) Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion. Br J Cancer 69: 858
21. Ma J, Verweij J, Planting AST, Kolker HJ, Loos WJ, Boer-Denert M de, Burg MEL van de, Stoter G (1996) Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Cancer Chemother Pharmacol 37: 382
22. Mellish KJ, Kelland LR, Harrap KR (1993) In vitro platinum drug chemosensitivity of human squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 68: 240
23. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for DNA from human nucleated cells. Nucleic Acids Res 16: 1215
24. Mistry P, Kelland LR, Abel G, Sidhal S, Harrap KR (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight ovarian carcinoma cell lines. Br J Cancer 64: 215
25. Reed E, Sauerhoff S, Poirier MC (1988) Quantitation of platinum-DNA binding after therapeutic levels of drug exposure -a novel use of graphite furnace spectrophotometry. At Spectrosc 9: 93
26. Roninson IB, Abelson HT, Housman DE, Howell N, Varshavsky A (1984) Amplification of specific DNA sequences with multi-drug resistance in Chinese hamster ovarian cells. Nature 309: 626
27. Scanlon KJ, Safirstein RL, Thies H, Gross RB, Waxman S, Guttenplan JB (1983) Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) Derivatives in L1210 murine leukemia cells. Cancer Res 43: 4211
28. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T (1991) Cisplatin resistance in human cancers. Pharmacol Ther 52: 385
29. Schellens JHM, Bont-Krootjes BBH de, Kolker HJ, Stoter G, Ma J (1995) Cisplatin-resistant subline of a human ovarian cancer cell line. In: Zeller WJ, D'Incalci M, Newell DR (eds) Novel approaches in anticancer drug design. Molecular modelling new treatment strategies. (Contributions to Oncology, vol 49) Basel, Karger, p 88
30. Sharp SY, Rogers PM, Kelland LR (1995) Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexyl-amine platinum(IV) (JM216) in human ovarian carcinoma cell line: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1: 981
31. Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA (1992) Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 52: 5674
32. Versantvoort CHM, Broxterman HJ, Pinedo HM, Vries EGE, Feller N, Kuiper CM (1992) Energy - cancer cell lines without P-glycoprotein expression. Cancer Res 52: 17
33. Vries EGE de, Mueller M, Meijer C, Jansen PLM, Mulder NH (1995) Role of glutathione S-conjugate pump in cisplatin resistance. J Natl Cancer Inst 87: 537